Artiva Biotherapeutics vs Celldex Therapeutics
Artiva Biotherapeutics and Celldex Therapeutics are similar in size: $0 and $1.5m of revenue in their latest fiscal years. Celldex Therapeutics grew faster (-78.0% against -100.0%). Artiva Biotherapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Artiva BiotherapeuticsARTV, 2025 | Celldex TherapeuticsCLDX, 2025 |
|---|---|---|
| Revenue | $0 | $1.5m |
| Revenue growth | -100.0% | -78.0% |
| Net income | −$83.9m | −$259m |
| Operating margin | — | -18599.8% |
| Net margin | — | -16748.0% |
| Return on equity | -56.5% | -40.6% |
| Free cash flow | −$79.3m | −$214m |
| Cash | $26.7m | $28.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 104 | 198 |
| Market value | $165m | $2.32bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 2 sales |